Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 family 21 subfamily A member 1, pseudogene (CYP21A1P) is a *non-functional pseudogene* located in the major histocompatibility complex (MHC) class III region on chromosome 6. It arose as a duplicated copy of the functional CYP21A2 gene but contains multiple mutations (including point mutations, frame shifts, and deletions) that prevent it from encoding a functional 21-hydroxylase enzyme. Although CYP21A1P is transcribed, its mRNA does not result in a functional protein. The high sequence similarity between CYP21A1P and CYP21A2 makes molecular analysis of the functional gene challenging and allows for intergenic recombination events, which can cause pathogenic variants in CYP21A2 underlying most cases of congenital adrenal hyperplasia (CAH)[2][3][4][5][6][7][8]. CYP21A1P is not itself a therapeutic target, enzyme, or receptor, but its presence and sequence can indirectly affect disease through genetic recombination mechanisms; thus, it is classified as a pseudogene and is not directly implicated in therapeutic strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome P450 family 21 subfamily A member 1, pseudogene (CYP21A1P).